S. Karabulut, "Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.," BMC CANCER , vol.24, no.1, pp.114, 2024
Karabulut, S. 2024. Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.. BMC CANCER , vol.24, no.1 , 114.
Karabulut, S., (2024). Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.. BMC CANCER , vol.24, no.1, 114.
Karabulut, Senem. "Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.," BMC CANCER , vol.24, no.1, 114, 2024
Karabulut, Senem. "Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.." BMC CANCER , vol.24, no.1, pp.114, 2024
Karabulut, S. (2024) . "Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.." BMC CANCER , vol.24, no.1, p.114.
@article{article, author={Senem KARABULUT}, title={Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.}, journal={BMC CANCER}, year=2024, pages={114} }